EL7.AI
GeopoliticsMedium•19 November 2026•
1 min read

US Security Commission Warns of Chinese Dominance in Global Drug Supply Chains

Key Facts

1The National Security Commission on Emerging Biotechnology warned that China is intensifying efforts to control the entire drug supply chain.
2Major drugmakers including AstraZeneca and Pfizer have invested heavily in Chinese biotechs to boost their product pipelines.
3The Chinese government proposed new export restrictions on certain technologies, including cell and gene therapy platforms.

The National Security Commission on Emerging Biotechnology warned that China is intensifying efforts to control the entire global drug supply chain. Axios reported that a commission report cautioned that licensing deals between Western pharmaceutical companies and Chinese firms are transferring critical know-how and capital to Beijing, potentially creating a dangerous dependency.

Major drugmakers including AstraZeneca and Pfizer have invested heavily in Chinese biotechs to boost their product pipelines, while the Chinese government has proposed new export restrictions on technologies such as cell and gene therapy platforms. In market activity, AZN closed at $178.76 and PFE closed at $28.06 on November 18, 2026.

Open on chart